Jose Silva

Further, with only 23% of patients coming back for re-resection, it's all the more important to do a complete TURBT right from the start.

Further, with only 23% of patients coming back for re-resection, it's all the more important to do a complete TURBT right from the start.

Social media and PR by Chi Ding. Administrative support provided by Judy De La Cruz.

Social media and PR by Chi Ding. Administrative support provided by Judy De La Cruz.

Social media and PR by Chi Ding. Administrative support provided by Judy De La Cruz.

Hello, everyone, and welcome back to Backtable Urology Podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and backtable.com. Now a quick word from our sponsors. This discussion is brought to you by Myros Pharmaceuticals, the makers of Kisatrex, testosterone on the canoid capsule.

Hello, everyone, and welcome back to Backtable Urology Podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and backtable.com. Now a quick word from our sponsors. This discussion is brought to you by Myros Pharmaceuticals, the makers of Kisatrex, testosterone on the canoid capsule.

Hello, everyone, and welcome back to Backtable Urology Podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and backtable.com. Now a quick word from our sponsors. This discussion is brought to you by Myros Pharmaceuticals, the makers of Kisatrex, testosterone on the canoid capsule.

Kisatrex is an oral medication indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. In a clinical study of men with low testosterone, nearly 9 out of 10 had normal testosterone levels after 90 days.

Kisatrex is an oral medication indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. In a clinical study of men with low testosterone, nearly 9 out of 10 had normal testosterone levels after 90 days.

Kisatrex is an oral medication indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. In a clinical study of men with low testosterone, nearly 9 out of 10 had normal testosterone levels after 90 days.

As a cash-only oral form of TRT, Kaisertrex simplifies the administration of testosterone therapy while enabling revenue generation for your practice. Discover how Kaisertrex can benefit your patients and your practice. Learn more at kaisertrex.com. Now, back to the show. This is Jose Silva, your host this week. And I'm happy to introduce our guest, the legend, Dr. Abraham Morgenthaler.

As a cash-only oral form of TRT, Kaisertrex simplifies the administration of testosterone therapy while enabling revenue generation for your practice. Discover how Kaisertrex can benefit your patients and your practice. Learn more at kaisertrex.com. Now, back to the show. This is Jose Silva, your host this week. And I'm happy to introduce our guest, the legend, Dr. Abraham Morgenthaler.

As a cash-only oral form of TRT, Kaisertrex simplifies the administration of testosterone therapy while enabling revenue generation for your practice. Discover how Kaisertrex can benefit your patients and your practice. Learn more at kaisertrex.com. Now, back to the show. This is Jose Silva, your host this week. And I'm happy to introduce our guest, the legend, Dr. Abraham Morgenthaler.

Dr. Morgenthaler completed his residency in urology from Harvard Medical School and then joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an associate professor of urology at Harvard Medical School, founder and past president of the Androgen Society, and senior editor of Journal of Androgens Clinical Research and Therapeutics.

Dr. Morgenthaler completed his residency in urology from Harvard Medical School and then joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an associate professor of urology at Harvard Medical School, founder and past president of the Androgen Society, and senior editor of Journal of Androgens Clinical Research and Therapeutics.

Dr. Morgenthaler completed his residency in urology from Harvard Medical School and then joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an associate professor of urology at Harvard Medical School, founder and past president of the Androgen Society, and senior editor of Journal of Androgens Clinical Research and Therapeutics.

In 1999, Dr. Morgan Taller founded Men's Health Boston, the first men's health center in the U.S., focusing on sexual, reproductive, and hormonal health for men. Dr. Mogenthaler is a leading international figure in the fields of testosterone therapy, prostate cancer, and male sexuality. He's a physician, an author, and a speaker. Dr. Mogenthaler, welcome to Backtable.

In 1999, Dr. Morgan Taller founded Men's Health Boston, the first men's health center in the U.S., focusing on sexual, reproductive, and hormonal health for men. Dr. Mogenthaler is a leading international figure in the fields of testosterone therapy, prostate cancer, and male sexuality. He's a physician, an author, and a speaker. Dr. Mogenthaler, welcome to Backtable.

In 1999, Dr. Morgan Taller founded Men's Health Boston, the first men's health center in the U.S., focusing on sexual, reproductive, and hormonal health for men. Dr. Mogenthaler is a leading international figure in the fields of testosterone therapy, prostate cancer, and male sexuality. He's a physician, an author, and a speaker. Dr. Mogenthaler, welcome to Backtable.